

Cohort descriptions and outcomes															
Cohort	Cohort description							Inclusion criteria				Outcomes			
	Reference	Year	N	Country	Study years	Md patient age (years)	Md PSA-level (ng/mL)	Max c T stage	Max PSA-level (ng/mL)	Grade group	Max No. Pos. Cores	Md follow-up	Risk of prostate cancer metastasis	Risk of prostate cancer death	Risk of switching to active treatment
MSK	(14)	2020	2,664	USA	2000–2017	62	5	T2C	N/A	GG1	No restrictions	4.3 years	0.1% (95% CI: 0.03–0.4) at 5 years 0.6% (95% CI: 0.2–2.0) at 10 years 1.5% (95% CI: 0.4–5.2) at 15 years	1/2,664 died 0% (95% CI: 0–1) at 10 years	24% (95% CI: 22–26) at 5 years; 36% (95% CI: 32–39) at 10 years; 42% (95% CI: 36–49) at 15 years
MSK	(13)	2020	219	USA	2000–2017	67	5	T3A	N/A	GG2	3	3.1 years	No distant metastasis, 2 men with lymph node metastatic disease	No deaths	39% (95% CI: 30–48) at 5 years; 51% (95% CI: 40–63) at 10 years
Johns Hopkins	(12)	2020	1,818	USA	1995–2018	66 very low risk; 67 low risk	4.6 very low risk; 5.9 low risk	T2A	10	GG1	2	5.0 years	1 additional man with metastatic disease 0.1% (95% CI: 0.04–0.6) at 10 years 0.1% (95% CI: 0.04–0.6) at 15 years	4/1818 died 0.1% (95% CI: 0.01–0.4) at 10 years 0.1% (95% CI: 0.01–0.4) at 15 years	36% (95% CI: 34–38) at 5 years; 48% (95% CI: 45–51) at 10 years; 52% (95% CI: 49–55) at 15 years
UCSF	(15)	2019	1,916	USA	1994–2017	62	5.5	T2	N/A	GG1 (86.6%) GG2, 1 core (6.9%); GG2, 2+ cores (6.5%)	No restrictions	5.5 years	4 men with bone metastatic disease	1/1,916 died	23.4% at 5.5 years
PRIAS	(18)	2016	5,302	Multi-country	2006–2016	66	5.7	T2C	10	2006: GG1; 2012: GG1 (99%) GG2 (1%)	2006: 2 positive cores 2015: no restrictions	622 were followed >5 years, 107 were followed >7.5 years	8 men with metastatic disease	1/5,302 died	52% at 5 years; 73% at 10 years
Miami	(25)	2010	230	USA	1992–2009	64	4.76	T2C	10	GG1	2	2.7 years	Not reported	No deaths	14% at 2.8 years
Royal Marsden	(24)	2013	471	UK	2002–2011	66	6.4	T2B	15	GG1 or GG2 (if >65 years)	<50% of total biopsy cores	5.7 years	2 men with metastatic disease	2/471 died	11% (95% CI: 8–14) at 2 years; 30% (95% CI: 25–35) at 5 years
ProtecT	(17)	2016	545	UK	1999–2009	62	4.6	T2	20	GG1 (77%); GG2–3 (20%); GG4–5 (2%)	N/A	10 years	33 men with metastatic disease	8/545 died (3 with GG1, 5 with GG2+) 0.6% (95% CI: 0.2%–1.7%) at 5 years 1.2% (95% CI: 0.5%–2.6%) at 10 years	54.8% (95% CI: 50.4–59.3%) at 10 years
Toronto	(22)	2015	993	Canada	1995–2013	68		T2C	20	1995: GG1; 2000: GG1 (84%) GG2 (13%)		6.4 years	28 men with metastatic disease 2.8% at 15 years	15/993 died 1.9% at 10 years 5.7% at 15 years	24.3% at 5 years; 36.5% at 10 years; 45% at 15 years; 45% at 20 years
Copenhagen	(21)	2015	317	Denmark	2002–2013	65	6.6	T2A	10	GG1	3	3.7 years	Not reported	No deaths	39.5% at 5 years
St Vincents	(23)	2015	650	Australia	1998–2012	63	6.2	T2B	10	GG1	<20% of total biopsy cores	4.6 years	0% at 7.5 years	0% at 7.5 years	43% at 5 years; 55% at 10 years; 58% at 15 years
Goteborg	(19)	2016	474	Sweden	1995–2014	66		T2C	<10 low risk; <20 intermediate risk	GG1 or GG2		8.0 years	1.0% (95% CI: 0–4) at 10 years 7.0% (95% CI: 3–16) at 15 years	6/474 died 0.5% (95% CI: 0–3) at 10 years 4.0% (95% CI: 2–10) at 15 years	53% (95% CI: 47–59) at 10 years; 66% (95% CI: 57–75) at 15 years
Canary PASS	(20)	2016	905	USA	2008–2013	63		T2C	20	GG1 or GG2		2.3 years	No metastasis	No deaths	12% at 2 years; 19% at 2.3 years; 29% at 5 years; 50% at 10 years
Milan	(16)	2017	818	Italy	2005–2016	66	5.7	T2A	10	GG1	<25% of total biopsy cores	4.9 years	No metastasis	No deaths	29% (95% CI: 27–31) at 2 years; 50% (95% CI: 48–52) at 5 years